3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Virus Diseases
1
Tumor Virus Infections
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
Cisplatin
21
pembrolizumab
16
Gemcitabine
16
Paclitaxel
15
Radiotherapy
14
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
9
Cetuximab
9
Magnetic Resonance Spectroscopy
8
Radiation
7
padeliporfin
6
Specimen Handling
6
Oxaliplatin
6
Fluorouracil
6
Drug Therapy
6
Docetaxel
6
Capecitabine
6
Bevacizumab
6
anlotinib
5
Nivolumab
5
Irinotecan
5
Erlotinib Hydrochloride
5
Celecoxib
5
poly ICLC
4
fludarabine
4
Standard of Care
4
Sorafenib
4
Leucovorin
4
Ipilimumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled